Live Quote · OTCARTHHealthcare· Biotechnology

Arch Therapeutics, Inc.

$0.00 0.00%(+$0.00)
TickerSpark Score
53/100
Mixed
60
Valuation
40
Profitability
100
Growth
36
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTH research report →

52-Week Range0% of range
Low
$0.00
Current
$0.00
High
$1.57
Company Overviewwww.archtherapeutics.com

About the company

Arch Therapeutics, Inc. , operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform.

CEO
Terrence W. Norchi
IPO
2013
Employees
8
HQ
Framingham, MA, US

Price Chart

-99.94% · this period
$1.49$0.75$0.00May 23Nov 21May 27
Valuation
Market Cap
$444
P/E
-0.00
P/S
0.01
P/B
-0.00
EV/EBITDA
-1.39
Div Yield
0.00%
Profitability
Gross Margin
-3.22%
Op Margin
-6661.67%
Net Margin
-9221.43%
ROE
119.36%
ROIC
268.33%
Growth & Income
Revenue
$75.72K · 383.80%
Net Income
$-6,982,836 · -63.31%
EPS
$-2.27 · 36.24%
Op Income
$-5,044,483
FCF YoY
24.18%
Performance & Tape
52W High
$1.57
52W Low
$0.00
50D MA
$0.18
200D MA
$0.32
Beta
4.03
Avg Volume
2.12K

Get TickerSpark's AI analysis on ARTH

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Aug 31, 23ABRAMS MICHAEL Sother20,584
Aug 31, 23ABRAMS MICHAEL Sbuy10,292
Aug 31, 23Norchi Terrence Wother13,724
Aug 31, 23Norchi Terrence Wbuy6,862
Aug 31, 23Hicks Laurenceother20,584
Aug 31, 23Hicks Laurencebuy10,292
Nov 10, 22DHILLON PUNITother250,000
Nov 10, 22Fish Guy L.other250,000
Nov 10, 22Hicks Laurenceother250,000
Nov 10, 22Yrigoyen Danother500,000
Coverage · ARTH

Our ARTH coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on ARTH yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate ARTH report →
Internal Compare

Similar companies

Peers in the same neighborhood.